Experience
MannKind to Acquire scPharmaceuticals for up to $360 Million
August 25, 2025
Cooley advised MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, on its definitive merger agreement to acquire scPharmaceuticals for up to $360 million
Related contacts
Barbara Borden
Senior Counsel, San Diego
Rowook Park
Partner, San Diego
Julia Kim
Special Counsel, New York
Mischi a Marca
Partner, San Francisco
Adam J. Longenbach
Partner, New York
Matthew S. Scarano
Associate, San Diego
Megan Browdie
Partner, Washington, DC
Ross Eberly
Partner, Santa Monica
Todd Gluth
Partner, San Diego
Eric Greig
Partner, Washington, DC
Asa Henin
Partner, San Diego
Phil Mitchell
Partner, New York
Alessandra Murata
Partner, Palo Alto
Stella Sarma
Partner, Brussels
Charity Williams
Partner, San Diego
Julia R. Brinton
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Emily Mason
Special Counsel, Santa Monica
Randy Sabett
Special Counsel, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
David Dalton
Associate, Santa Monica
Sharon Davidov
Associate, New York
Jameson Davis
Associate, Boston
Athina Gaki
Associate, Brussels
Tony P. Guan
Associate, Santa Monica
Josh Himmelstern
Associate, San Diego
Michelle Hunt
Associate
Wyatt Kernell
Associate, Colorado
Bomin Kim
Associate, New York
Allison Kutner
Associate, New York
Jacob R. Lahana
Associate, Santa Monica
Eileen Leman
Associate, Los Angeles
Walter Musgrave
Associate, San Diego
Joseph Perry
Associate, Reston
Allie Pilmer
Associate, San Diego
Breanna Qin
Associate, Palo Alto
Vittoria Rainone
Associate, San Diego
Bartholomäus Regenhardt
Associate, Brussels
Brittany K. Wightman
Associate, San Diego
Jennifer Fitzpatrick
Paralegal Specialist, Washington, DC
Related Practices & Industries
Inmagene Biopharmaceuticals Completes Merger With Ikena Oncology [UPDATED]
July 25, 2025
Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).
Related contacts
Lila Hope
Partner, Palo Alto
Rama Padmanabhan
Partner, San Diego
Patrick Loofbourrow
Partner, Singapore
Asa Henin
Partner, San Diego
Lindsey O'Crump
Associate, Washington, DC
Brittany K. Wightman
Associate, San Diego
Jiqiang Lin
Associate, New York
Leina Verrier
Associate, Santa Monica
Ross Eberly
Partner, Santa Monica
Stephanie Gentile
Partner, New York
Christopher Kimball
Partner, Washington, DC
Xander Lee
Partner, Santa Monica
Phil Mitchell
Partner, New York
Howard Morse
Senior Counsel, Washington, DC
Alessandra Murata
Partner, Palo Alto
Jean Park
Partner, New York
Aaron Pomeroy
Partner, Colorado
Michelle Garcia Schulman
Partner, Reston
Ellie Seber
Partner, Santa Monica
Marty Schenker
Senior Counsel , San Francisco
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Andrew Epstein
Special Counsel, Seattle
Stella Sarma
Partner, Brussels
Karen Tsai
Special Counsel, Washington, DC
Bin Wang
Special Counsel, Palo Alto
Robert Eisenbach
Of Counsel, San Francisco
Rajdeep Roger Bains
Associate, San Diego
Julia R. Brinton
Special Counsel, Washington, DC
Adrienne Beaudoin Deshmukh
Associate, Reston
Jeremy M. Exelbert
Associate, New York
Zack Gong
Associate, Shanghai
Rick Jantz
Associate, Santa Monica
Wyatt Kernell
Associate, Colorado
Rebeca Kinslow
Associate, San Diego
Hilda Li
Associate, Hong Kong
Lunga Su
Associate, Shanghai
Novak Topalovic
Associate, San Diego
Tania Soris
Associate, Washington, DC
Monica Xu
Special Counsel, Shanghai
Sai Yarramalla
Associate, Palo Alto
Andy Zachrich
Associate, San Francisco
Patricia Myers
Paralegal Specialist, Colorado
Jake Ironfield
Transactional Quantitative Analyst, New York
Related Practices & Industries
Inmagene Biopharmaceuticals Announces Merger With Ikena Oncology
December 23, 2024
Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).
Related contacts
Lila Hope
Partner, Palo Alto
Rama Padmanabhan
Partner, San Diego
Patrick Loofbourrow
Partner, Singapore
Asa Henin
Partner, San Diego
Lindsey O'Crump
Associate, Washington, DC
Brittany K. Wightman
Associate, San Diego
Jiqiang Lin
Associate, New York
Leina Verrier
Associate, Santa Monica
Ross Eberly
Partner, Santa Monica
Stephanie Gentile
Partner, New York
Christopher Kimball
Partner, Washington, DC
Xander Lee
Partner, Santa Monica
Phil Mitchell
Partner, New York
Howard Morse
Senior Counsel, Washington, DC
Alessandra Murata
Partner, Palo Alto
Jean Park
Partner, New York
Aaron Pomeroy
Partner, Colorado
Michelle Garcia Schulman
Partner, Reston
Ellie Seber
Partner, Santa Monica
Marty Schenker
Senior Counsel , San Francisco
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Andrew Epstein
Special Counsel, Seattle
Stella Sarma
Partner, Brussels
Karen Tsai
Special Counsel, Washington, DC
Bin Wang
Special Counsel, Palo Alto
Robert Eisenbach
Of Counsel, San Francisco
Rajdeep Roger Bains
Associate, San Diego
Julia R. Brinton
Special Counsel, Washington, DC
Adrienne Beaudoin Deshmukh
Associate, Reston
Jeremy M. Exelbert
Associate, New York
Zack Gong
Associate, Shanghai
Rick Jantz
Associate, Santa Monica
Wyatt Kernell
Associate, Colorado
Rebeca Kinslow
Associate, San Diego
Hilda Li
Associate, Hong Kong
Lunga Su
Associate, Shanghai
Novak Topalovic
Associate, San Diego
Tania Soris
Associate, Washington, DC
Monica Xu
Special Counsel, Shanghai
Sai Yarramalla
Associate, Palo Alto
Andy Zachrich
Associate, San Francisco
Patricia Myers
Paralegal Specialist, Colorado
Jake Ironfield
Transactional Quantitative Analyst, New York
Related Practices & Industries
Tvardi Therapeutics Announces Merger With Cara Therapeutics
December 18, 2024
Cooley advised Tvardi Therapeutics, a privately held, clinical-stage biopharmaceutical company focused on the development of novel, oral, small-molecule therapies targeting STAT3 to treat fibrosis-driven diseases, on its definitive merger agreement to combine in an all-stock transaction with Cara Therapeutics (Nasdaq: CARA), a development-stage biopharmaceutical company that has been leading a new treatment paradigm to improve the lives of patients suffering from pruritus.
Related contacts
Div Gupta
Partner, New York
Rama Padmanabhan
Partner, San Diego
Carlos Ramirez
Partner, San Diego
Lindsey O'Crump
Associate, Washington, DC
Brittany K. Wightman
Associate, San Diego
Michael Bergmann
Partner, Washington, DC
Ross Eberly
Partner, Santa Monica
Lila Hope
Partner, Palo Alto
Xander Lee
Partner, Santa Monica
Phil Mitchell
Partner, New York
Howard Morse
Senior Counsel, Washington, DC
Francis Wheeler
Senior Counsel, Colorado
Natasha Leskovsek
Of Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Reid Hooper
Special Counsel, Washington, DC
Justin Kisner
Special Counsel, San Diego
Dani Nazemian
Special Counsel, San Diego
Stella Sarma
Partner, Brussels
Karen Tsai
Special Counsel, Washington, DC
Julia R. Brinton
Special Counsel, Washington, DC
Navya Dasari
Associate, New York
Jeremy Gentile
Associate, San Diego
Carly E. Gibbons
Associate, Chicago
Wyatt Kernell
Associate, Colorado
Jiqiang Lin
Associate, New York
Kelly McCormick
Associate, San Francisco
Jonathan Perez-Reyzin
Associate, San Diego
Carly Robinson
Associate, Reston
Jesse Schulman
Associate, Colorado
Rebecca Siegel
Associate, San Francisco
Tania Soris
Associate, Washington, DC
Patricia Myers
Paralegal Specialist, Colorado
Jake Ironfield
Transactional Quantitative Analyst, New York
Brian Mitchell
Transactional Quantitative Analyst, San Diego
Related Practices & Industries
Gracell Biotechnologies Agrees to Acquisition by AstraZeneca for up to $1.2 Billion
December 26, 2023
Cooley advised Gracell Biotechnologies, a global clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for the treatment of cancer and autoimmune diseases, on its definitive agreement to be acquired by AstraZeneca.
Related contacts
Rama Padmanabhan
Partner, San Diego
Rowook Park
Partner, San Diego
Izzy Lubarsky
Partner, New York
Brittany K. Wightman
Associate, San Diego
Rajdeep Roger Bains
Associate, San Diego
Will Cai
Partner, Hong Kong
Patrick Loofbourrow
Partner, Singapore
Jie Zhang
Counsel, Hong Kong
Hilda Li
Associate, Hong Kong
Alessandra Murata
Partner, Palo Alto
Charity Williams
Partner, San Diego
Xander Lee
Partner, Santa Monica
Phil Mitchell
Partner, New York
Megan Browdie
Partner, Washington, DC
Christopher Kimball
Partner, Washington, DC
Ross Eberly
Partner, Santa Monica
Natasha Leskovsek
Of Counsel, Washington, DC
Rena Kaminsky
Special Counsel, Palo Alto
Stella Sarma
Partner, Brussels
Andrew Epstein
Special Counsel, Seattle
Dillon Martinson
Special Counsel, Washington, DC
Patrick Sharma
Associate, Santa Monica
Allison Kutner
Associate, New York
Eileen Leman
Associate, Los Angeles
Sarah Oliai
Associate, Washington, DC
Related Practices & Industries
Related news and events
Press Release
Inmagene Biopharmaceuticals Completes Merger With Ikena Oncology [UPDATED]
July 25, 2025
Admissions and credentials
California